Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of Advagraf (tacrolimus) systemic exposure in pediatric solid organ transplant recipients
2011-000078-80Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus in kidney allograft rejection, Hepatic transplant rejection (LTR) and Immune disorder (2 arms), sponsored by Astellas Pharma. Primary endpoint: Primary Pharmacokinetic Variables. Started Aug 2011; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejectionHepatic transplant rejection (LTR)Immune disorder
Beyond the preview
Go deeper on 2011-000078-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000078-80.